FDA issued a warning letter to Singapore-based TSP Solutions after a remote records request under section 704(a)(4) of the FD&C Act showed no adequate assay, impurity or microbiological testing for OTC sunscreen products, and asked for retrospective testing of in-date retain samples. Separately, the MHRA Inspectorate reported, six months into the UK’s reformed clinical trials regulations, that around 3–5% of applications fail validation because of missing documents, unsigned forms or files that do not meet OCR requirements. Common pharmaceutical deficiencies include IMPs or placebos left off the medicine information form, missing labelling justifications, unclear manufacturing-site details and incomplete GMP evidence or QP declarations.
Regulators increasingly judge quality systems on the documents sent to them, without visiting the site, so records must prove control on their own. Relying on a supplier certificate instead of actual testing, or filing an incomplete dossier, now leads directly to enforcement action or a delayed study start.
Run a mock 704(a)(4) records request, and add a joint QA–CMC–clinical-supply completeness review before every submission that checks a sample of outsourced certificates against specifications and raw data.
https://fda.watch/articles/tsp-solutions-pte-ltd-fda-warning-letter-cgmp-finished-pharmaceuticals
BethAri can run these readiness simulations and help close the gaps they expose.